Improving antibody-drug therapy for acute myeloid leukemia
Pharmacokinetic / Pharmacodynamic Optimization of ADC Therapy for Acute Myeloid Leukemia
This study is looking for better and safer ways to treat people with acute myeloid leukemia (AML) by developing new targeted therapies that focus on cancer cells while reducing side effects for healthy ones.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project ID | NIH-11006313 on NIH RePORTER |
What this research studies
This research focuses on enhancing the safety and effectiveness of antibody-drug conjugate (ADC) therapy for patients with acute myeloid leukemia (AML). It involves creating new monoclonal antibodies and nanobodies that specifically target proteins overexpressed in AML cells. The study will also explore innovative strategies to reduce side effects by using bispecific constructs and payload binding selectivity enhancers, which aim to minimize toxicity to healthy tissues while effectively targeting cancer cells. Through these approaches, the research seeks to optimize treatment outcomes for AML patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with acute myeloid leukemia who are seeking advanced therapeutic options.
Not a fit: Patients with other types of leukemia or those who do not have acute myeloid leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients with acute myeloid leukemia.
How similar studies have performed: Previous research has shown promise in using targeted therapies for leukemia, suggesting that this approach could yield significant advancements.
Where this research is happening
Amherst, United States
- State University of New York at Buffalo — Amherst, United States (Active)
Researchers
- Principal investigator: Balthasar, Joseph P — State University of New York at Buffalo
- Study coordinator: Balthasar, Joseph P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.